Kraig Biocraft Laboratories' Lead Sericulture Expert Joins Recombinant Spider Silk Production Team at New Rearing Facility in Southeast Asia

Rhea-AI Summary

Kraig Biocraft Laboratories (OTCQB: KBLB), a biotechnology company specializing in spider silk technology, announced that Dr. Nirmal Kumar, their lead sericulture expert, has joined the production team at their new Southeast Asian rearing facility.

Dr. Kumar will oversee the first production cycle at the new center, focusing on BAM-1 spider silk production. His responsibilities include supervising the development of an expanded BAM-1 egg production center and testing lab. The company is also exploring partnerships with secondary processing providers and is in discussions with a potential customer regarding a custom spider silk thread order.

This development marks a significant step in Kraig Labs' transition to continuous production of their first recombinant spider silk hybrid line, positioning the company to meet growing market demand.

Positive

• Expansion of production capabilities with second rearing facility now fully operational
• Potential customer discussions underway for custom spider silk thread order
• Development of expanded BAM-1 egg production center and testing lab to support scale-up
• Strategic exploration of secondary processing partnerships in the region

Negative

• Production scale remains unspecified and unproven
• No concrete timeline provided for commercial production targets
• Customer discussions still in preliminary stages without confirmed orders

News Market Reaction

+3.22%

1 alert

+3.22% News Effect

On the day this news was published, KBLB gained 3.22%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

ANN ARBOR, Mich., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, today announced that Dr. Nirmal Kumar, the Company's lead sericulture expert, has arrived in Southeast Asia to support the production team at its recently established second rearing facility.

Dr. Kumar will work directly with the Company's operations team on the first production cycle at the new center, ensuring the highest levels of quality and efficiency as Kraig Labs continues to expand its BAM-1 spider silk output. His expertise in silkworm rearing and hybrid development has been instrumental to the Company's success, and his on-site leadership marks a significant step for Kraig Labs in its transition to continuous production of BAM-1, its first recombinant spider silk hybrid line.

During this time with the team, Dr. Kumar will also oversee the build-out of an expanded BAM-1 egg production center and testing lab, designed to support ongoing scale-up and maintain production continuity across multiple rearing centers. These facilities will form the backbone of the Company's long-term commercialization strategy as Kraig Labs ramps BAM-1 production to meet growing demand.

Additionally, Dr. Kumar will explore opportunities with secondary processing providers in the region, including spinners capable of supporting downstream applications for recombinant spider silk. As part of this effort, Kraig Labs is currently in discussions with a potential customer regarding a custom order of spider silk thread, a crucial step toward demonstrating the versatility and scalability of BAM-1 in specialty textile markets.

"Having Dr. Kumar on the ground with our production team at this critical stage provides invaluable expertise with our second rearing center now fully online," said Kim Thompson, Kraig Labs' Founder and CEO. "His leadership not only strengthens our current BAM-1 production cycle but also sets the stage for the expansion and processing partnerships that will allow us to meet near-term customer opportunities and long-term market demand."

The Company's ability to execute on both upstream production and downstream processing highlights its unique position at the intersection of biotechnology and traditional sericulture, as Kraig Labs works to establish spider silk as a commercial reality.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company's investor conference at www.kraiglabs.com/videos or on the Company's YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news

* For a description of our historical leadership in this technology, please follow this link https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.
(720) 288-8495
ir@KraigLabs.com

FAQ

What is the significance of Dr. Nirmal Kumar joining KBLB's Southeast Asian facility?

Dr. Kumar, as KBLB's lead sericulture expert, will oversee the first production cycle at the new facility and lead the development of an expanded BAM-1 egg production center and testing lab, crucial for scaling up spider silk production.

What is BAM-1 and how is Kraig Biocraft Laboratories producing it?

BAM-1 is Kraig Biocraft's first recombinant spider silk hybrid line, produced through biotechnology and traditional sericulture methods at their rearing facilities.

What are Kraig Biocraft Laboratories' current commercial developments for spider silk?

The company is in discussions with a potential customer for custom spider silk thread orders and is exploring partnerships with secondary processing providers in Southeast Asia.

Where are Kraig Biocraft Laboratories' spider silk production facilities located?

The company operates rearing facilities in Southeast Asia, with a recently established second facility that has now become fully operational.

What is Kraig Biocraft Laboratories' strategy for scaling up spider silk production?

KBLB is expanding through multiple rearing centers, developing an expanded BAM-1 egg production center and testing lab, and seeking partnerships with secondary processing providers to meet market demand.